These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 2987577)
41. [The vaccine for hepatitis B virus. Definition of criteria for its use]. Sturm JA Rev Paul Med; 1985; 103(1):23-31. PubMed ID: 2994199 [No Abstract] [Full Text] [Related]
42. Hepatitis BeAg in chronic asymptomatic hepatitis B surface antigen carriers and in primary hepatocellular carcinoma patients. Tswana SA Cent Afr J Med; 1986 May; 32(5):113-6. PubMed ID: 3028639 [No Abstract] [Full Text] [Related]
43. Hepatitis-B surface antigen and hepatocellular carcinoma in Taiwan. With special reference to types and localization of HBsAg in the tumor cells. Hsu HC; Lin WS; Tsai MJ Cancer; 1983 Nov; 52(10):1825-32. PubMed ID: 6313175 [TBL] [Abstract][Full Text] [Related]
44. Anti-HBc titer in relation to the etiological role of hepatitis B virus in primary hepatocellular carcinoma. Furuta S; Nagata A; Kiyosawa K; Akahane Y; Koike Y; Sahara T; Oda M; Mayumi M; Tsuda F Acta Hepatogastroenterol (Stuttg); 1977 Feb; 24(1):3-6. PubMed ID: 192028 [TBL] [Abstract][Full Text] [Related]
46. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. Momosaki S; Nakashima Y; Kojiro M; Tabor E J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475 [TBL] [Abstract][Full Text] [Related]
47. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Ioannou GN; Splan MF; Weiss NS; McDonald GB; Beretta L; Lee SP Clin Gastroenterol Hepatol; 2007 Aug; 5(8):938-45, 945.e1-4. PubMed ID: 17509946 [TBL] [Abstract][Full Text] [Related]
48. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Yano Y; Yamashita F; Sumie S; Ando E; Fukumori K; Kiyama M; Oyama T; Kuroki S; Kato O; Yamamoto H; Tanaka M; Sata M Am J Gastroenterol; 2002 Jan; 97(1):156-61. PubMed ID: 11808941 [TBL] [Abstract][Full Text] [Related]
49. Hepatitis B viral infection: part I. Clinical features. Dzik WH; Alter HJ Am Fam Physician; 1982 Aug; 26(2):119-26. PubMed ID: 6285684 [TBL] [Abstract][Full Text] [Related]
50. [Analysis of hepatitis virus infection in hepatocellular carcinoma patients receiving surgical operation in China and Japan]. Yuan P; Tang W; Wen J; Li QM; Luo H; Liang BH; Zheng QM; Wei L Zhonghua Yu Fang Yi Xue Za Zhi; 2005 Sep; 39(5):332-4. PubMed ID: 16266545 [TBL] [Abstract][Full Text] [Related]
51. Hepatocellular carcinoma, positive Australia (hepatitis-associated) antigen and sarcoidosis. Myerson RM; Soroush A; Skerrett PV Am J Dig Dis; 1971 Sep; 16(9):857-62. PubMed ID: 4329070 [No Abstract] [Full Text] [Related]
52. [Hepatitis B virus surface antigen (HBsAg) in human hepatocellular carcinoma and its surrounding tissues of liver (author's transl)]. Wang WL; Zang JS; Wang BY; Liu WB; Zhu CW; Ding HY; Yan PS; Liu YF Zhonghua Zhong Liu Za Zhi; 1979; 1(2):101-5. PubMed ID: 233358 [No Abstract] [Full Text] [Related]
53. Analysis of risk factors for hepatocellular carcinoma that is negative for hepatitis B surface antigen (HBsAg). Shimada S; Aizawa R; Abe H; Suto S; Miyakawa Y; Aizawa Y Intern Med; 2003 May; 42(5):389-93. PubMed ID: 12793707 [TBL] [Abstract][Full Text] [Related]
54. Decreasing frequency, with time, of hepatitis B surface antigen positive liver biopsy in hepatitis, cirrhosis, and hepatocellular carcinoma. Senba M; Nakamura T; Toda T; Matsumura H Lancet; 1988 Mar; 1(8585):588-9. PubMed ID: 2894519 [No Abstract] [Full Text] [Related]
55. Antibody to hepatitis B core antigen in patients with hepatocellular carcinoma. Kubo Y; Okuda K; Hashimoto M; Nagasaki Y; Ebata H Gastroenterology; 1977 Jun; 72(6):1217-20. PubMed ID: 192626 [TBL] [Abstract][Full Text] [Related]
56. Hepatitis B surface antigen and cirrhosis in hepatocellular carcinoma. Gahukamble LD; Sudarsanam D Indian J Cancer; 1982; 19(5):234-6. PubMed ID: 6299933 [No Abstract] [Full Text] [Related]
58. Forecasting the development of primary hepatocellular carcinoma by the use of risk factors: studies in West Africa. Larouzé B; Blumberg BS; London WT; Lustbader ED; Sankalé M; Payet M J Natl Cancer Inst; 1977 Jun; 58(6):1557-61. PubMed ID: 68119 [TBL] [Abstract][Full Text] [Related]
59. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. Xuan SY; Xin YN; Chen H; Shi GJ; Guan HS; Li Y World J Gastroenterol; 2007 Mar; 13(12):1870-4. PubMed ID: 17465484 [TBL] [Abstract][Full Text] [Related]